Roadblocks confronting widespread dissemination and deployment of Organs on Chips
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Organ on Chip platforms hold significant promise as alternatives to animal models or traditional cell cultures, both of which poorly recapitulate human pathophysiology and human level responses. Within the last 15 years, we have witnessed seminal scientific developments from academic laboratories, a flurry of startups and investments, and a genuine interest from pharmaceutical industry as well as regulatory authorities to translate these platforms. This Perspective identifies several fundamental design and process features that may act as roadblocks that prevent widespread dissemination and deployment of these systems, and provides a roadmap to help position this technology in mainstream drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, they typically employ polydimethylsiloxane (PDMS), which can absorb gases and small molecules like drugs, and hence, is not a preferable material for developing organs on chips meant for disease modeling and drug discovery.17”
From Retinal organoid chip: engineering a physiomimetic oxygen gradient for optimizing long term culture of human retinal organoids (2025) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 2×
“Following the landmark publication of Lung on a Chip in 2010, and robust support from funding agencies, Organ on Chip technology has becomeone of the fastestgrowing areas in bioengineering 12 .”
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Microfluidic devices fabricated in Poly(dimethylsiloxane) for biological studies
Sia, S. K., & Whitesides, G. M. (2003) · ELECTROPHORESIS · doi:10.1002/elps.200305584 · Cited by 1,717 · cited 1×
“PDMS has become the material of choice for Organs on Chips due to properties that make it suitable for biological applications, such as low cytotoxicity, optical transparency, gas permeability, and established fabrication methods 64,65 .”
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589 · cited 4×
“Additionally, Organ on Chip devices are designed to utilize an ever-growing array of analytic techniques to assess the functionality and biomechanics of the tissues cultured within them, such as live-cell imaging, analyte collection, and electrophysiological readouts 2,3,16,29 – 32 .”
InfluentialEstimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585 · cited 1×
“Despite this huge investment of time and money, the clinical success rate of drug approval stands between 10 and 20% 52,53 .”
Becker, H. (2002) · Talanta · doi:10.1016/s0039-9140(01)00594-x · Cited by 1,187
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029 · cited 1×
“Therefore, a systems engineering approach is necessary to design and manage the various components required for a practical platform 80 – 82 .”
Materials for Microfluidic Chip Fabrication
Ren, K., Zhou, J., & Wu, H. (2013) · Accounts of Chemical Research · doi:10.1021/ar300314s · Cited by 974
Zhang, Y. S., Aleman, J., Shin, S. R., Kilic, T., Kim, D., Mousavi Shaegh, S. A., Massa, S., Riahi, R., Chae, S., Hu, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612906114 · Cited by 833
A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling
Zhao, Y., Rafatian, N., Feric, N. T., Cox, B. J., Aschar-Sobbi, R., Wang, E. Y., Aggarwal, P., Zhang, B., Conant, G., Ronaldson-Bouchard, K., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.042 · Cited by 610 · cited 1×
“These micro fl uidic devices can range from simple systems with one or more related cell types 7 – 10 to more complex multichannel systems that utilize porous membranes and multiple cell cultures to mimic tissue interfaces, such as those in the lungs or kidney 11 – 15 .”
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576 · cited 4×
“As a result, an ecosystem of new biotechnology companies has emerged to help move Organs on Chips out of academic research labs and into the drug discovery space 33,46 .”
InfluentialMusah, S., Mammoto, A., Ferrante, T. C., Jeanty, S. S. F., Hirano-Kobayashi, M., Mammoto, T., Roberts, K., Chung, S., Novak, R., Ingram, M., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0069 · Cited by 538 · cited 1×
“These micro fl uidic devices can range from simple systems with one or more related cell types 7 – 10 to more complex multichannel systems that utilize porous membranes and multiple cell cultures to mimic tissue interfaces, such as those in the lungs or kidney 11 – 15 .”
Micromilling: a method for ultra-rapid prototyping of plastic microfluidic devices
Guckenberger, D. J., de Groot, T. E., Wan, A. M. D., Beebe, D. J., & Young, E. W. K. (2015) · Lab on a Chip · doi:10.1039/c5lc00234f · Cited by 513 · cited 2×
“Micromachined platforms are also more accessiblefor in-houseprototyping asmicromillingmachine caneasily be setup in most lab spaces without a cleanroom 78,79 .”
BackgroundA multi-organ chip with matured tissue niches linked by vascular flow
Ronaldson-Bouchard, K., Teles, D., Yeager, K., Tavakol, D. N., Zhao, Y., Chramiec, A., Tagore, S., Summers, M., Stylianos, S., Tamargo, M., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00882-6 · Cited by 512 · cited 5×
“…and fl uidic parameters, such as shear stress, mechanical strain and compression, and perfusate composition, which includes but is not limited to additional suspended cells (e.g. immune cells), stimulants (e.g. hormones and drugs), and gaseous species (e.g. oxygen and carbon dioxide) 1,5,28 .”
InfluentialReproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511 · cited 2×
“Recapitulation of a speci fi c disease microenvironment ensures that the ef fi cacy of a drug — both in terms of its function and its targeting to a speci fi c organ system — can beappropriatelyvalidatedintheearlystagesofdrugdevelopment 34 – 36 .”
Small molecule absorption by PDMS in the context of drug response bioassays
van Meer, B. J., de Vries, H., Firth, K. S. A., van Weerd, J., Tertoolen, L. G. J., Karperien, H. B. J., Jonkheijm, P., Denning, C., IJzerman, A. P., & Mummery, C. L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.062 · Cited by 502 · cited 1×
“Despite the adoption of PDMS as the standard material for prototyping Organs on Chips, many limitations have been identi fi ed 5,66 .”
Reengineering Translational Science: The Time Is Right
Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002747 · Cited by 479 · cited 1×
“A recurring culprit has been animal models, which are not suf fi ciently predictive of the safety nor ef fi cacy of therapeutic compounds in humans 29,56,57 .”
A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle
Xiao, S., Coppeta, J. R., Rogers, H. B., Isenberg, B. C., Zhu, J., Olalekan, S. A., McKinnon, K. E., Dokic, D., Rashedi, A. S., Haisenleder, D. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14584 · Cited by 479 · cited 1×
“A notable example of a complex Organ on Chip is the EVATAR system for female reproductive systems 14,25 – 27 , which includes separate organ modules for the ovary, fallopian tube, uterus, cervix, and liver within a micro fl uidic system to simulate the in vivo female reproductive tract.”
Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
High-Throughput Screening: today’s biochemical and cell-based approaches
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.024 · Cited by 387 · cited 1×
“While traditional high-throughput drug screening methods are effec-tiveateliminatingineffectivedrugs,theprocessisoftennotconducive for these early stage systemic toxicity studies 58 .”
Multiorgan-on-a-Chip: A Systemic Approach To Model and Decipher Inter-Organ Communication
Picollet-D’hahan, N., Zuchowska, A., Lemeunier, I., & Le Gac, S. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.11.014 · Cited by 379 · cited 2×
“Additionally, Organ on Chip devices are designed to utilize an ever-growing array of analytic techniques to assess the functionality and biomechanics of the tissues cultured within them, such as live-cell imaging, analyte collection, and electrophysiological readouts 2,3,16,29 – 32 .”
Generation of vascularized brain organoids to study neurovascular interactions
Sun, X.-Y., Ju, X.-C., Li, Y., Zeng, P.-M., Wu, J., Zhou, Y.-Y., Shen, L.-B., Dong, J., Chen, Y.-J., & Luo, Z.-G. (2022) · eLife · doi:10.7554/elife.76707 · Cited by 378
Zamprogno, P., Wüthrich, S., Achenbach, S., Thoma, G., Stucki, J. D., Hobi, N., Schneider-Daum, N., Lehr, C.-M., Huwer, H., Geiser, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01695-0 · Cited by 348 · cited 1×
“Just over a decade after its discovery, this method was adapted to layer intricate micro fl uidic channel geometries and porous structures to develop the fi rst Organ on Chip, and the majority of subsequent Organ on Chip designs 5,12,63 .”
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337 · cited 2×
“Recapitulation of a speci fi c disease microenvironment ensures that the ef fi cacy of a drug — both in terms of its function and its targeting to a speci fi c organ system — can beappropriatelyvalidatedintheearlystagesofdrugdevelopment 34 – 36 .”
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Organs-on-a-chip models for biological research
Vunjak-Novakovic, G., Ronaldson-Bouchard, K., & Radisic, M. (2021) · Cell · doi:10.1016/j.cell.2021.08.005 · Cited by 248 · cited 1×
“While traditional 2D culture methods have served the scienti fi c community well over the past century, the development of Organ on Chip devices has improved the ability to culture more complex 3D engineered and ex-vivo tissues 1 – 6 .”
Azizgolshani, H., Coppeta, J. R., Vedula, E. M., Marr, E. E., Cain, B. P., Luu, R. J., Lech, M. P., Kann, S. H., Mulhern, T. J., Tandon, V., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00067e · Cited by 225
Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K., & Pistollato, F. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231157756 · Cited by 219
Fuchs, S., Johansson, S., Tjell, A. Ø., Werr, G., Mayr, T., & Tenje, M. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01110 · Cited by 213 · cited 1×
“Therefore, a systems engineering approach is necessary to design and manage the various components required for a practical platform 80 – 82 .”
An evaluation framework for new approach methodologies (NAMs) for human health safety assessment
Parish, S. T., Aschner, M., Casey, W., Corvaro, M., Embry, M. R., Fitzpatrick, S., Kidd, D., Kleinstreuer, N. C., Lima, B. S., Settivari, R. S., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104592 · Cited by 211 · cited 1×
“A Fit for Purpose statement indicates thatthe Organon Chipassay or approach has “ good enough ” validation/quali fi cation information to support its context of use 89,90 .”
Assembling human brain organoids
Paşca, S. P. (2019) · Science · doi:10.1126/science.aau5729 · Cited by 208
A human lung alveolus-on-a-chip model of acute radiation-induced lung injury
Dasgupta, Q., Jiang, A. R., Wen, A. M., Mannix, R. J., Man, Y., Hall, S. R. R., Javorsky, E., & Ingber, D. E. (2023) · Nature Communications · doi:10.1038/s41467-023-42171-z · Cited by 179
Tao, T., Deng, P., Wang, Y., Zhang, X., Guo, Y., Chen, W., & Qin, J. (2022) · Advanced Science · doi:10.1002/advs.202103495 · Cited by 178
A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity
Jung, D. J., Shin, T. H., Kim, M., Sung, C. O., Jang, S. J., & Jeong, G. S. (2019) · Lab on a Chip · doi:10.1039/c9lc00496c · Cited by 176 · cited 1×
“Additionally, duetothelimitationsofthephotolithographicfabricationmethod,the channels in PDMS-based micro fl uidic devices have a maximum height of approximately 200 μ m 70 , which typically prohibits their use for culture of large spheroids and organoids.”
BackgroundBai, H., Si, L., Jiang, A., Belgur, C., Zhai, Y., Plebani, R., Oh, C. Y., Rodas, M., Patil, A., Nurani, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29562-4 · Cited by 171 · cited 1×
“A notable example of a complex Organ on Chip is the EVATAR system for female reproductive systems 14,25 – 27 , which includes separate organ modules for the ovary, fallopian tube, uterus, cervix, and liver within a micro fl uidic system to simulate the in vivo female reproductive tract.”
Vaginal microbiome-host interactions modeled in a human vagina-on-a-chip
Mahajan, G., Doherty, E. R., To, T., Sutherland, A. D., Grant, J. L., Junaid, A., Gulati, A., LoGrande, N., Izadifar, Z., Timilsina, S. S., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01400-1 · Cited by 169 · cited 1×
“A notable example of a complex Organ on Chip is the EVATAR system for female reproductive systems 14,25 – 27 , which includes separate organ modules for the ovary, fallopian tube, uterus, cervix, and liver within a micro fl uidic system to simulate the in vivo female reproductive tract.”
Impact of organ-on-a-chip technology on pharmaceutical R&D costs
Franzen, N., van Harten, W. H., Retèl, V. P., Loskill, P., van den Eijnden-van Raaij, J., & IJzerman, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.003 · Cited by 165 · cited 1×
“The value proposition for many of these startups focuses on providing better data for lead optimization 49 .”
Yamaguchi, S., Kaneko, M., & Narukawa, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12980 · Cited by 143 · cited 1×
“Despite this huge investment of time and money, the clinical success rate of drug approval stands between 10 and 20% 52,53 .”
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 143 · cited 1×
“The high attrition rate and overall decline in pharmaceutical research and development ef fi ciency has been well documented for over 30 years 54,55 .”
Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review
Cong, Y., Han, X., Wang, Y., Chen, Z., Lu, Y., Liu, T., Wu, Z., Jin, Y., Luo, Y., & Zhang, X. (2020) · Micromachines · doi:10.3390/mi11040381 · Cited by 140 · cited 1×
“…in series and parallel with each other can mimic the natural progression of a drug through different body compartments and provide more information on the potential systemic toxicity of a drug, aiding in the exclusion of toxic drugs at an earlier stage in the drug identi fi cation process 5,62 .”
Shirure, V. S., & George, S. C. (2017) · Lab on a Chip · doi:10.1039/c6lc01401a · Cited by 135 · cited 1×
“Signi fi cant work has been done to model the adsorptive properties of PDMS to optimize design parameters that minimize adsorption and mitigate the impact ofPDMS on drug discoverystudies 67,68 .”
BackgroundAtkins, J. T., George, G. C., Hess, K., Marcelo-Lewis, K. L., Yuan, Y., Borthakur, G., Khozin, S., LoRusso, P., & Hong, D. S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01033-x · Cited by 132 · cited 2×
“…these humanOrganon Chip models provide a signi fi cantly more accurate analysis of drug toxicities for potential new drugs compared to animal models in the pre-clinical phase, since they are also able to demonstrate side effects in human tissuethatmightnotbepresentinanimalmodels 36,38 – 40 .”
Journey of organ on a chip technology and its role in future healthcare scenario
Singh, D., Mathur, A. K., Arora, S., Roy, S., & Mahindroo, N. (2022) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2022.100246 · Cited by 132 · cited 1×
“As a result, an ecosystem of new biotechnology companies has emerged to help move Organs on Chips out of academic research labs and into the drug discovery space 33,46 .”
Organs-on-chips: Progress, challenges, and future directions
Low, L. A., & Tagle, D. A. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217700523 · Cited by 125
Kanton, S., & Paşca, S. P. (2022) · Development · doi:10.1242/dev.201120 · Cited by 112 · cited 1×
“More complex models can be created by fusing different types of organoids generated separately to reconstitute the interaction of multiple tissues 23,24 .”
Analysis of pharma R&D productivity – a new perspective needed
Schuhmacher, A., Hinder, M., Stein, A. V. S. U., Hartl, D., & Gassmann, O. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103726 · Cited by 112
Organ-on-a-chip technology for the study of the female reproductive system
Young, R. E., & Huh, D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.010 · Cited by 102
Organ-on-chip models for infectious disease research
Alonso‐Román, R., Mosig, A. S., Figge, M. T., Papenfort, K., Eggeling, C., Schacher, F. H., Hube, B., & Gresnigt, M. S. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01645-6 · Cited by 101
Introducing an automated high content confocal imaging approach for Organs-on-Chips
Peel, S., Corrigan, A. M., Ehrhardt, B., Jang, K.-J., Caetano-Pinto, P., Boeckeler, M., Rubins, J. E., Kodella, K., Petropolis, D. B., Ronxhi, J., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00829a · Cited by 98 · cited 1×
“Asidefromthe biological bene fi ts to drug discovery, Organ on Chip devices can also be run at a high throughput, meaning that many potential new drugs can be tested in rapid succession or even concurrently 41 – 43 .”
BackgroundOrganoid microphysiological system preserves pancreatic islet function within 3D matrix
Patel, S. N., Ishahak, M., Chaimov, D., Velraj, A., LaShoto, D., Hagan, D. W., Buchwald, P., Phelps, E. A., Agarwal, A., & Stabler, C. L. (2021) · Science Advances · doi:10.1126/sciadv.aba5515 · Cited by 97 · cited 1×
“…and fl uidic parameters, such as shear stress, mechanical strain and compression, and perfusate composition, which includes but is not limited to additional suspended cells (e.g. immune cells), stimulants (e.g. hormones and drugs), and gaseous species (e.g. oxygen and carbon dioxide) 1,5,28 .”
Self-citationOrgans-on-a-chip: a union of tissue engineering and microfabrication
Zhao, Y., Wang, E. Y., Lai, F. B. L., Cheung, K., & Radisic, M. (2023) · Trends in Biotechnology · doi:10.1016/j.tibtech.2022.12.018 · Cited by 93 · cited 1×
“While the foundationaluse of Organson Chipscan beattributedtotheacademic convergence of micro fl uidics, stem cell technology and tissue engineering 44,45 , one of the major current driving forces is the interest of pharmaceutical companies in applying this technology to drug development.”
Pamies, D., Ekert, J., Zurich, M.-G., Frey, O., Werner, S., Piergiovanni, M., Freedman, B. S., Keong Teo, A. K., Erfurth, H., Reyes, D. R., et al. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2024.03.009 · Cited by 88 · cited 1×
“A Fit for Purpose statement indicates thatthe Organon Chipassay or approach has “ good enough ” validation/quali fi cation information to support its context of use 89,90 .”
R&D Costs of New Medicines: A Landscape Analysis
Simoens, S., & Huys, I. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.760762 · Cited by 87 · cited 1×
“The estimated average cost for pharmaceutical companies to bring a new drug to market is approximately2 billion dollars, and the process cantake upwards of 15 years 33,51 .”
iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies
Palasantzas, V. E. J. M., Tamargo-Rubio, I., Le, K., Slager, J., Wijmenga, C., Jonkers, I. H., Kumar, V., Fu, J., & Withoff, S. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.002 · Cited by 86 · cited 1×
“While the foundationaluse of Organson Chipscan beattributedtotheacademic convergence of micro fl uidics, stem cell technology and tissue engineering 44,45 , one of the major current driving forces is the interest of pharmaceutical companies in applying this technology to drug development.”
Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies
Kroll, K. T., Mata, M. M., Homan, K. A., Micallef, V., Carpy, A., Hiratsuka, K., Morizane, R., Moisan, A., Gubler, M., Walz, A.-C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305322120 · Cited by 79
Baran, S. (2022) · ALTEX · doi:10.14573/altex.2112203 · Cited by 77 · cited 1×
“Quali fi cation scheme for any emerging technology or method is highly dependent upon the complexity of the questions (or mechanistic hypotheses) and the pathophysiology necessary to answer these questions 91,92 .”
Schneider, S., Gruner, D., Richter, A., & Loskill, P. (2021) · Lab on a Chip · doi:10.1039/d1lc00188d · Cited by 73 · cited 2×
“Plastic-based Organs on Chips can be fabricated by methods such as micromilling, 3D printing, and injection molding, that each offer a bene fi t at different stages of development and use 74,76 .”
MethodShroff, T., Aina, K., Maass, C., Cipriano, M., Lambrecht, J., Tacke, F., Mosig, A., & Loskill, P. (2022) · Open Biology · doi:10.1098/rsob.210333 · Cited by 68 · cited 1×
“Multiple Organ on Chip devices have been linked together to analyze the interactions between different organ functionsinthecontext ofdrugortoxindeliveryaswellasmetabolism and other multiorgan processes 5,16 – 21 .”
Recent trends of biomaterials and biosensors for organ-on-chip platforms
Gonçalves, I. M., Rodrigues, R. O., Moita, A., Hori, T., Kaji, H., Lima, R. A., & Minas, G. M. H. (2022) · Bioprinting · doi:10.1016/j.bprint.2022.e00202 · Cited by 66
Besser, R. R., Bowles, A. C., Alassaf, A., Carbonero, D., Claure, I., Jones, E., Reda, J. W., Wubker, L., Batchelor, W. M., Ziebarth, N., et al. (2019) · Biomaterials Science · doi:10.1039/c9bm01430f · Cited by 64
Self-citationKoning, J. J., Neves, C. T. R., Schimek, K. M. S., Thon, M., Spiekstra, S. W., Waaijman, T., de Gruijl, T. D., & Gibbs, S. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2021.824825 · Cited by 64 · cited 1×
“Aside from the direct effects of a potential drug on the tissue of interest, as would be screened for in high-throughput drug screenings, Organs on Chips have the ability to address systemic toxicity concerns via the linkage of several different types of Organ Chips 60 .”
Long‐Term Electrical and Mechanical Function Monitoring of a Human‐on‐a‐Chip System
Oleaga, C., Lavado, A., Riu, A., Rothemund, S., Carmona‐Moran, C. A., Persaud, K., Yurko, A., Lear, J., Narasimhan, N. S., Long, C. J., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201805792 · Cited by 63
Beyond PDMS and Membranes: New Materials for Organ-on-a-Chip Devices
Radisic, M., & Loskill, P. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00831 · Cited by 62 · cited 1×
“Plastic-based Organs on Chips can be fabricated by methods such as micromilling, 3D printing, and injection molding, that each offer a bene fi t at different stages of development and use 74,76 .”
Lenguito, G., Chaimov, D., Weitz, J. R., Rodriguez-Diaz, R., Rawal, S. A. K., Tamayo-Garcia, A., Caicedo, A., Stabler, C. L., Buchwald, P., & Agarwal, A. (2017) · Lab on a Chip · doi:10.1039/c6lc01504b · Cited by 58 · cited 1×
“3B), a subtractive manufacturing technique where selective removal of a base substrate generates microscale features in the substrate 3,4,61,77 .”
MethodSelf-citationTadenev, A. L. D., & Burgess, R. W. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09798-0 · Cited by 56 · cited 1×
“Important components of a pathway to adoption, and their inclusion in a drug discovery pipeline include Validation, de fi ning Context of Use, Quali fi cation as a drug discovery tool that is Fit for Purpose, and fi nally, Benchmarking 85,86 .”
Characterization of postfabricated parylene C coatings inside PDMS microdevices
Flueckiger, J., Bazargan, V., Stoeber, B., & Cheung, K. C. (2011) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2011.08.073 · Cited by 52 · cited 1×
“Aside from optimizing Organ on Chip geometries, PDMS adsorption has been combated by the use of coatings such as parylene c and polyphenol that decrease gas and solvent permeability in PDMS 68,69 .”
Developer’s Guide to an Organ-on-Chip Model
Rogal, J., Schlünder, K., & Loskill, P. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01536 · Cited by 52 · cited 1×
“This often requires a multidisciplinary engineering approach that combines mechanical, electrical, and computer engineering, with the added unique considerations of developing living biologic systems 83 .”
Keuper-Navis, M., Walles, M., Poller, B., Myszczyszyn, A., van der Made, T. K., Donkers, J., Eslami Amirabadi, H., Wilmer, M. J., Aan, S., Spee, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106853 · Cited by 52 · cited 1×
“As an alternative model to animal studies, Organs on Chips provide this safety information as well as genetic toxicity, pharmacokinetics, ADME (absorption, distribution, metabolism, and excretion), reproductive toxicity, and carcinogenicity 34,59 .”
Schneider, S., Bubeck, M., Rogal, J., Weener, H. J., Rojas, C., Weiß, M., Heymann, M., van der Meer, A. D., & Loskill, P. (2021) · Lab on a Chip · doi:10.1039/d1lc00494h · Cited by 49 · cited 1×
“Plastics such as polymethyl methacrylate (PMMAor acrylic)becamea popularalternative toPDMS because of their manufacturing ease and similar biological and experimentalbene fi ts,suchasopticalclarityandbeingbioinert 3,4,61,72,75 .”
BackgroundMicrophysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2022) · Cells Tissues Organs · doi:10.1159/000517422 · Cited by 48 · cited 1×
“However, Organ on Chip platforms face many technical and regulatory barriers that may complicate their widespread adoption in industrial use, and in pre-clinical trials 50 .”
Patterson, E. A., Whelan, M. P., & Worth, A. P. (2021) · Computational Toxicology · doi:10.1016/j.comtox.2020.100144 · Cited by 47 · cited 1×
“It also seeks to de fi ne the similarity between the endpoint generated by the Organ on Chip and the clinical readouts, as well as the predictive demonstration of clinically effective interventions producing a similar effect in anOrganon Chip platform 87 .”
Translating in vitro to in vivo and animal to human
Steger‐Hartmann, T., & Raschke, M. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.02.003 · Cited by 33
Network-Based Genomic Analysis of Human Oligodendrocyte Progenitor Differentiation
Pol, S. U., Polanco, J. J., Seidman, R. A., O’Bara, M. A., Shayya, H. J., Dietz, K. C., & Sim, F. J. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.07.007 · Cited by 32 · cited 1×
“…these humanOrganon Chip models provide a signi fi cantly more accurate analysis of drug toxicities for potential new drugs compared to animal models in the pre-clinical phase, since they are also able to demonstrate side effects in human tissuethatmightnotbepresentinanimalmodels 36,38 – 40 .”
Rapid prototyping for high-pressure microfluidics
Rein, C., Toner, M., & Sevenler, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-28495-2 · Cited by 32 · cited 1×
“PDMS has become the material of choice for Organs on Chips due to properties that make it suitable for biological applications, such as low cytotoxicity, optical transparency, gas permeability, and established fabrication methods 64,65 .”
Organ chip research in Europe: players, initiatives, and policies
da Silva, R. G. L., & Blasimme, A. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1237561 · Cited by 32 · cited 1×
“In Europe, the expansion of Organ on Chip technology is being driven by 3D organoidcompanies and micro fl uidic companies looking to add Organ on Chip applications to their portfolios 48 .”
Modular Microphysiological System for Modeling of Biologic Barrier Function
Ishahak, M., Hill, J. L., Amin, Q., Wubker, L., Hernandez, A., Mitrofanova, A. V., Sloan, A. J., Fornoni, A., & Agarwal, A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.581163 · Cited by 29 · cited 4×
“3B), a subtractive manufacturing technique where selective removal of a base substrate generates microscale features in the substrate 3,4,61,77 .”
InfluentialSelf-citationFisher, C. R., Medie, F. M., Luu, R. J., Gaibler, R. B., Mulhern, T. J., Miller, C. R., Zhang, C. J., Rubio, L. D., Marr, E. E., Vijayakumar, V., et al. (2023) · Cells · doi:10.3390/cells12222639 · Cited by 28 · cited 1×
“Asidefromthe biological bene fi ts to drug discovery, Organ on Chip devices can also be run at a high throughput, meaning that many potential new drugs can be tested in rapid succession or even concurrently 41 – 43 .”
COVID-19 highlights the model dilemma in biomedical research
Adhikary, P. P., Ul Ain, Q., Hocke, A. C., & Hedtrich, S. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00305-z · Cited by 25 · cited 1×
“A recurring culprit has been animal models, which are not suf fi ciently predictive of the safety nor ef fi cacy of therapeutic compounds in humans 29,56,57 .”
Alassaf, A., Tansık, G., Mayo, V., Wubker, L., Carbonero, D., & Agarwal, A. (2019) · The Analyst · doi:10.1039/c9an01339c · Cited by 24
Self-citationSood, A., Kumar, A., Gupta, V. K., Kim, C. M., & Han, S. S. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01080 · Cited by 22
Facile Macrocyclic Polyphenol Barrier Coatings for PDMS Microfluidic Devices
Reese, W. M., Burch, P., Korpusik, A. B., Liu, S. E., Loskill, P., Messersmith, P. B., & Healy, K. E. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202001274 · Cited by 20 · cited 14×
“Plastic micro fl uidic devices, fabricated through micromilling, 3D printing, and injection molding are a viable alternative to PDMS for Organs on Chips.”
InfluentialBesser, R. R., Bowles, A. C., Alassaf, A., Carbonero, D., Maciel, R. D. M., Saporta, M., & Agarwal, A. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00624-1 · Cited by 18 · cited 1×
“These micro fl uidic devices can range from simple systems with one or more related cell types 7 – 10 to more complex multichannel systems that utilize porous membranes and multiple cell cultures to mimic tissue interfaces, such as those in the lungs or kidney 11 – 15 .”
Self-citationLeclerc, C. A., Williams, S., Powe, C., Zepp, N., Lipworth, D., Pensini, E., & Collier, C. M. (2021) · Microfluidics and Nanofluidics · doi:10.1007/s10404-020-02414-7 · Cited by 15 · cited 2×
“Micromachined platforms are also more accessiblefor in-houseprototyping asmicromillingmachine caneasily be setup in most lab spaces without a cleanroom 78,79 .”
Alver, C. G., Álvarez-Cubela, S., Altilio, I., Hutchison, E., Warrner, E., Viso, M. E., Vitale, G., Oliver, D., Pastori, R. L., Domínguez‐Bendala, J., et al. (2024) · Lab on a Chip · doi:10.1039/d3lc00850a · Cited by 13 · cited 5×
“Additionally, Organ on Chip devices are designed to utilize an ever-growing array of analytic techniques to assess the functionality and biomechanics of the tissues cultured within them, such as live-cell imaging, analyte collection, and electrophysiological readouts 2,3,16,29 – 32 .”
BackgroundMethodInfluentialSelf-citationAjay, A. K. (2022) · Kidney360 · doi:10.34067/kid.0007172021 · Cited by 9 · cited 1×
“These micro fl uidic devices can range from simple systems with one or more related cell types 7 – 10 to more complex multichannel systems that utilize porous membranes and multiple cell cultures to mimic tissue interfaces, such as those in the lungs or kidney 11 – 15 .”
BackgroundBowles, A. C., Ishahak, M., Glover, S. J., Correa, D., & Agarwal, A. (2019) · Integrative Biology · doi:10.1093/intbio/zyz027 · Cited by 8
Self-citationMicroelectrode Array based Functional Testing of Pancreatic Islet Cells
Alassaf, A., Ishahak, M., Bowles, A. C., & Agarwal, A. (2020) · Micromachines · doi:10.3390/mi11050507 · Cited by 7 · cited 1×
“Additionally, Organ on Chip devices are designed to utilize an ever-growing array of analytic techniques to assess the functionality and biomechanics of the tissues cultured within them, such as live-cell imaging, analyte collection, and electrophysiological readouts 2,3,16,29 – 32 .”
Self-citationMcDuffie, D., Alver, C. G., Suthar, B., Helm, M., Oliver, D., Burgess, R. A., Barr, D., Thomas, E., & Agarwal, A. (2023) · Lab on a Chip · doi:10.1039/d3lc00382e · Cited by 6 · cited 3×
“3B), a subtractive manufacturing technique where selective removal of a base substrate generates microscale features in the substrate 3,4,61,77 .”
BackgroundMethodSelf-citationHeads on! Designing a qualification framework for organ-on-chip
(2024) · ALTEX · doi:10.14573/altex.2401231 · Cited by 5 · cited 1×
“Quali fi cation process is also intended to explain how results of the approach will be used in decision-making 88 .”
MethodIntegrated platform for operating and interrogating organs-on-chips
Ishahak, M., Birman, L., Carbonero, D., Hill, J. L., Hernandez, A., Rawal, S., & Agarwal, A. (2019) · Analytical Methods · doi:10.1039/c9ay01663e · Cited by 4 · cited 1×
“Organization elements at this stage can help identify key features of the design and decrease time required to address potential failure modes 84 .”
BackgroundSelf-citation
Cited by
Advances in 3D Organoids and Organ‐on‐a‐Chip Systems for Biomedical Research
Sakthivel, V., Dharshan, S. S., Namasivayam, S. K. R., & Arockiaraj, J. (2026) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbma.70028 · Cited by 57
Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects
Nair, D. G., & Weiskirchen, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb47010007 · Cited by 53
A review of organ-on-chip fabrication methods: From early developments to overcoming inert barriers
Olaizola‐Rodrigo, C., Bayona, C., Oliván, S., & Monge, R. (2025) · iScience · doi:10.1016/j.isci.2025.113992 · Cited by 35
“125 Almost all PDMS-based OOC platforms discussed above retain a separating membrane between compartments, preventing direct tissue-tissue contact and limiting intercellular cross-talk (e.g., Figures 4B and 4C, and 4E).”
Harnessing Intelligence from Brain Cells In Vitro
Kagan, B. J., Habibollahi, F., Watmuff, B., Azadi, S. A., Doensen, F., Loeffler, A., Byun, S. H., Servais, B., Desouza, C., Abu-Bonsrah, K. D., et al. (2025) · The Neuroscientist · doi:10.1177/10738584251321438 · Cited by 32
Lei, Y., Zhang, Y., Zhou, L., Zhou, Z., Rothbauer, M., Bai, L., Xu, J., Xie, D., Mobasheri, A., Zhang, X., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.10.013 · Cited by 32
“This act opened the door for the expanded use of NAMs like organoids and OoCs, accelerating the translation of these innovative technologies into clinical applications and potentially revolutionizing drug development and regulatory processes [110].”
Metadata
- Authors
- Alver, C. G., Drabbe, E., Ishahak, M., & Agarwal, A.
- Affiliations
- University of Miami (US)
- Corresponding author
- Agarwal, Ashutosh
- Venue
- Nature Communications
- Published
- 2024-06-15
- Volume
- 15
- Issue
- 1
- Pages
- 5118-5118
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11180125
- OpenAlex
- W4399704632
- Cited by
- 74
- References
- 93
- Citations by year
- 2026: 45 · 2025: 27 · 2024: 2
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F31DK118860, UH3DK122638, F31DK132916)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA233363)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Keywords
- organ-on-a-chip, microfluidic organ models, alternative to animal models, 3D cell culture, drug discovery, translational barriers, technology deployment, human pathophysiology, regulatory acceptance
- MeSH terms
- Microphysiological Systems, Animals, Drug Industry, Humans, Drug Discovery, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.